Proprietary Work

Global Value Dossiers

Global dossiers to support the market access function, these synthesize relevant clinical and economic research, publicly accessible literature and market strategy and present an evidence-based value rationale. We have developed these for pipeline or approved products in a variety of therapeutic areas… cardiology, gastroenterology, infectious disease, neurology, oncology, psychiatry, rheumatology, …

Formulary submission packages

Over 200 submissions to Canadian and US formulary decisionmakers prepared to date, including clinical and economic background and rationale, budget impact models and reports, product-specific and audience-specific forms and reports

Presentation materials

Posters, slides, handouts, and other presentation materials for in-house or external dissemination of health outcomes information, research and strategy (Posters, Podiums and Keynote presentations, classroom or conference room materials)

Backgrounders, Briefing Documents & Reports (for example…)

• Systematic review of the natural history of HPV infection and associated diseases in females 9-26
• Systematic literature review on the clinical and economic burden and treatment of heart failure in Canada
• Gap analysis for diagnostic medical device used for the detection of H. pylori. in Ontario
• Human Papilloma virus (HPV): homosexual transmission and burden of disease
• Human Papilloma virus (HPV): heterosexual transmission and burden of disease
• A common road map for data synthesis, clinical practice guidelines and policymaking—applications of the EVIDEM framework
• Antithrombotic therapy for prevention of stroke in atrial fibrillation: disease burden and unmet needs
• Étude de la faisabilité de la mise en place d'une banque de lait maternel chez Héma-Québec
• Canadian Workplace Health Promotion programs; health and economic outcomes
• Aspects of workplace disease management and employee health in Canada
• Global clinical and economic burden of nosocomial infections - with a focus on S aureus and post-surgical infection
• Health policy study examining the cost of oncology medicines in Canada
• Literature review on the natural history of human papillomavirus (HPV) infection and associated diseases in men
• The value of pharmaceutical innovation in Canada
• The natural history of human papillomavirus (HPV) infection in adult women
• Epidemiological and etiological aspects of CABP and cSSSi
• Clinical, pharmacoeconomic and quality of life evidence for direct renin inhibitors, angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors for all indications
• Systematic review of the biomedical literature on the topic of stable angina, its epidemiology, treatment and burden
• Comprehensive review of the biomedical literature on the topic of risk of metabolic syndrome in patients treated with the atypical antipsychotics
• Systematic review of biomedical literature: rotavirus epidemiology and burden of illness in the middle east and Europe
• Systematic literature review and gap analysis: negative pressure wound healing
• Comprehensive literature review of opioid-induced constipation: epidemiology, health care utilization, quality of life and clinical
• Antithrombotic therapy for prevention of stroke in atrial fibrillation: evidence on disease burden and unmet need
• An analysis of sub-optimal coagulation treatment for atrial fibrillation
• A comprehensive review of the burden of disease and unmet needs for prevention and treatment of venous thromboembolism (VTE) in the medically ill
• The association between anal intraepithelial neoplasia (AIN) and anal cancer
• Atrial fibrillation patient subgroup analysis
• Costs of urinary tract infections in Germany, the UK and USA
• The role of HTA in healthcare decisionmaking: a report on selected drug policy issues in Canada
• Aspects of the natural history of human papillomavirus (HPV) infection and associated diseases
• A systematic review of health related quality of life and ostomy treatment
• Assessing the future of 'authorized generics' in a number of  market segments - US, UK, France & Japan
• Renal anemia and EPO: the pre-dialysis renal anemia market
• Venous leg ulcers: patient compliance and impact on clinical and economic outcomes
• Canadianizing an economic model comparing intensive atorvastatin treatment with standard simvastatin treatment based on data from the CARDS trial
• Cytomegalovirus (CMV): Biomarkers of congenital infection & disease and relationships
• Vaccination programs for pneumococcal disease in adults (≥50 years): Evidence for disease burden and unmet needs
• Vaccination programs for pneumococcal disease in the pediatric population: Evidence on disease burden and unmet needs
• Pneumococcal vaccine development in the post-Prevnar era: key issues in epidemiology and economic modeling
• Glaucoma (IOP) treatment in Canada
• Overview of HPV Vaccination
• Overview of hip fracture
• Reimbursement and J-Code incentives for pharmacological stress test drugs (adenosine, dipyridamole, dobutamine) in the US
• Overview of DPP-4 inhibitors for diabetes
• Costs of short and long term disability in Type II diabetes relating to poor glycemic control from the perspective of 3rd party payers
• The burden of major depressive disorder (MDD)
• Tabulation of health and economic outcome measures (number needed-to-treat and cost per quality adjusted life year) used for medical interventions in Canada and the US
• Osteoarthritis and rheumatoid arthritis in Canada
• Pharmacoeconomic assessment of medication for treatment of ulcers and gastroesophageal reflux disease (GERD)
• Comparison of NSAID + PPI treatment versus COX-2 selective inhibitors on NSAID-related gastrointestinal events
• Status of Paget's Disease:  treatment and current practice in Canada
• Vitamin D and osteoporosis
• Marketing of pharmaceutical products in the 1980s and 1990s
• Sarcopenia and cachexia: burden of illness and management patterns
• Congestive heart failure (CHF) in Ontario and Quebec
• Rates of nausea & vomiting and sexual dysfunction with SSRI & SNRI antidepressant use, impact on compliance, and effect of compliance on depression outcomes
• Cost-of-illness of acromegaly and associated co-morbidities
• Acromegaly and associated comorbidities
• Haloperidol treatment for schizophrenia
• Use of biologics in Canada
• Risperidone treatment for schizophrenia
• Oral inflammation and human systemic disease [Full Text available]
• Drivers of healthcare cost growth in the US
• Treatment of dyslipidemia
• The limitations of statin therapy in the treatment of hypercholesterolemia
• Prostate cancer treatment in Canada: current status and research investment
• Salmon calcitonin nasal spray (Miacalcin) for osteoporosis treatment
• Economic and quality of life outcomes in renal and oncology-related anemia
• The science behind Colgate Total
• The market for non-pharmacological approaches to deep vein thrombosis (DVT) treatment
• Managing escalating pharmaceutical costs: challenges facing pharmacy services
• Economic evaluation and quality of life in solid organ transplantation
• New approaches to therapeutic intervention in cardiac hypertrophy
• Forces influencing inpatient hospital costs in the United States
• The role of Triclosan/Copolymer dentifrice in the prevention and control of periodontal disease

Patient Information & Educational Materials …)

© 2012 BioMedCom™ Consultants Inc. All rights reserved.